144 related articles for article (PubMed ID: 8683171)
41. Heparin coating of an extracorporeal circuit partly improves hemostasis after cardiopulmonary bypass.
Boonstra PW; Gu YJ; Akkerman C; Haan J; Huyzen R; van Oeveren W
J Thorac Cardiovasc Surg; 1994 Jan; 107(1):289-92. PubMed ID: 8283898
[TBL] [Abstract][Full Text] [Related]
42. Safety of heparin-coated circuits in primates during deep hypothermic cardiopulmonary bypass.
Sistino JJ; Michler RE; Mongero LB; Schwartz A; Marboe C; Geiman R; Kwiatkowski P
J Extra Corpor Technol; 1993; 25(1):15-21. PubMed ID: 10148570
[TBL] [Abstract][Full Text] [Related]
43. Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass.
Gu YJ; van Oeveren W; Akkerman C; Boonstra PW; Huyzen RJ; Wildevuur CR
Ann Thorac Surg; 1993 Apr; 55(4):917-22. PubMed ID: 8466349
[TBL] [Abstract][Full Text] [Related]
44. Effects of Duraflo II heparin-coated cardiopulmonary bypass circuits on the coagulation system, endothelial damage, and cytokine release in patients with cardiac operation employing aprotinin and steroids.
Inui K; Shimazaki Y; Watanabe T; Takahashi T; Minowa T; Takeda H; Yanagawa N; Sotoda Y
Artif Organs; 1999 Dec; 23(12):1107-12. PubMed ID: 10619929
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of Duraflo II heparin immobilized cardiopulmonary bypass circuits.
Tong SD; Rolfs MR; Hsu LC
ASAIO Trans; 1990; 36(3):M654-6. PubMed ID: 2252775
[TBL] [Abstract][Full Text] [Related]
46. Heparin-coated cardiopulmonary bypass circuits and 25% reduction of heparin dose in coronary artery surgery--a clinical study.
Borowiec J; Thelin S; Bagge L; van der Linden J; Thörnö E; Hansson HE
Ups J Med Sci; 1992; 97(1):55-66. PubMed ID: 1523735
[TBL] [Abstract][Full Text] [Related]
47. Heparin-coated cardiopulmonary bypass circuits reduce blood cell trauma. Experiments in the pig.
Thelin S; Bagge L; Hultman J; Borowiec J; Nilsson L; Thorelius J
Eur J Cardiothorac Surg; 1991; 5(9):486-91. PubMed ID: 1931093
[TBL] [Abstract][Full Text] [Related]
48. Biocompatibility of heparin-coated circuits in pediatric cardiopulmonary bypass.
Kagisaki K; Masai T; Kadoba K; Sawa Y; Nomura F; Fukushima N; Ichikawa H; Ohata T; Suzuki K; Taketani S; Matsuda H
Artif Organs; 1997 Jul; 21(7):836-40. PubMed ID: 9212969
[TBL] [Abstract][Full Text] [Related]
49. Complement consumption during cardiopulmonary bypass: comparison of Duraflo II heparin-coated and uncoated circuits in fully heparinized patients.
Hamulu A; Dişcigil B; Ozbaran M; Calkavur T; Kara E; Kokuludağ A; Büket S; Bilkay O
Perfusion; 1996 Jul; 11(4):333-7. PubMed ID: 8884862
[TBL] [Abstract][Full Text] [Related]
50. Biocompatibility of cardiopulmonary bypass circuit with new polymer Senko E-Ternal Coating™.
Fukui T; Nishida H; Takanashi S
Perfusion; 2015 Oct; 30(7):572-9. PubMed ID: 25837980
[TBL] [Abstract][Full Text] [Related]
51. Enhanced blood conservation and improved clinical outcome after valve surgery using heparin-bonded cardiopulmonary bypass circuits.
Shapira OM; Aldea GS; Zelingher J; Volpe C; Fitzgerald C; DeAndrade K; Lazar HL; Shemin RJ
J Card Surg; 1996; 11(5):307-17. PubMed ID: 8969375
[TBL] [Abstract][Full Text] [Related]
52. Biocompatibility of heparin-coated circuits used in cardiopulmonary bypass.
Pekna M; Borowiec J; Fagerhol MK; Venge P; Thelin S
Scand J Thorac Cardiovasc Surg; 1994; 28(1):5-11. PubMed ID: 7939508
[TBL] [Abstract][Full Text] [Related]
53. Clinical performance and biocompatibility of novel hyaluronan-based heparin-bonded extracorporeal circuits.
Gunaydin S; Mccusker K; Vijay V
J Extra Corpor Technol; 2005 Sep; 37(3):290-5. PubMed ID: 16350383
[TBL] [Abstract][Full Text] [Related]
54. Effects of two differently heparin-coated extracorporeal circuits on markers for brain and myocardial dysfunction.
Flom-Halvorsen HI; Ovrum E; Brosstad F; Tangen G; Ringdal M; Oystese R
Perfusion; 2002 Sep; 17(5):339-45. PubMed ID: 12243437
[TBL] [Abstract][Full Text] [Related]
55. Safe use of heparin-coated bypass circuits incorporating a pump-oxygenator.
Jones DR; Hill RC; Vasilakis A; Hollingsed MJ; Graeber GM; Gustafson RA; Cruzzavala JL; Murray GF
Ann Thorac Surg; 1994 Apr; 57(4):815-8; discussion 818-9. PubMed ID: 8166524
[TBL] [Abstract][Full Text] [Related]
56. 'High dose' aprotinin and heparin-coated circuits: clinical efficacy and inflammatory response.
Parolari A; Alamanni F; Gherli T; Salis S; Spirito R; Foieni F; Rossi F; Bertera A; Oddono P; Biglioli P
Cardiovasc Surg; 1999 Jan; 7(1):117-27. PubMed ID: 10073771
[TBL] [Abstract][Full Text] [Related]
57. Influence of two blood conservation techniques (cardiotomy reservoir versus cell-saver) on biocompatibility of the heparin coated cardiopulmonary bypass circuit during coronary revascularization surgery.
Borowiec JW; Bozdayi M; Jaramillo A; Nilsson L; Venge P; Henze A
J Card Surg; 1997; 12(3):190-7. PubMed ID: 9395949
[TBL] [Abstract][Full Text] [Related]
58. A prospective randomized trial comparing the clinical effectiveness and biocompatibility of heparin-coated circuits and PMEA-coated circuits in pediatric cardiopulmonary bypass.
Itoh H; Ichiba S; Ujike Y; Douguchi T; Kasahara S; Arai S; Sano S
Perfusion; 2016 Apr; 31(3):247-54. PubMed ID: 26228276
[TBL] [Abstract][Full Text] [Related]
59. Coagulation, fibrinolysis, and cell activation in patients and shed mediastinal blood during coronary artery bypass grafting with a new heparin-coated surface.
Johnell M; Elgue G; Larsson R; Larsson A; Thelin S; Siegbahn A
J Thorac Cardiovasc Surg; 2002 Aug; 124(2):321-32. PubMed ID: 12167793
[TBL] [Abstract][Full Text] [Related]
60. Heparin-coated cardiopulmonary bypass circuit: clinical effects in pediatric cardiac surgery.
Miyaji K; Hannan RL; Ojito J; Jacobs JP; White JA; Burke RP
J Card Surg; 2000; 15(3):194-8. PubMed ID: 11414605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
